Cassava Sciences Inc
NASDAQ:SAVA
Cassava Sciences Inc
NASDAQ:SAVA
Price:
1.815
USD
-0.27%
Market Closed
Market Cap:
$87.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cassava Sciences Inc
NASDAQ:SAVA
|
US |
|
BabyTree Group
HKEX:1761
|
CN |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SIX:TIBN
|
CH |
Relative Value
There is not enough data to reliably calculate the relative value of SAVA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SAVA
Relative Value
Base Case
Not Available
Multiples Across Competitors
SAVA Competitors Multiples
Cassava Sciences Inc Competitors
Cassava Sciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cassava Sciences Inc
NASDAQ:SAVA
|
87.7m USD | 0 | -0.8 | 0.2 | 0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
860.3B USD | 13.2 | 41.7 | 28.1 | 30 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.9B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.8 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.1B GBP | 4.9 | 28 | 15.6 | 21.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.3B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 5.1 | 20.6 | 12.7 | 16.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
114.7B USD | 2.4 | 16.3 | 6.9 | 8.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
